Open access
Open access
Powered by Google Translator Translator

Hematology (all articles)

Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

 


M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.

23 Jun, 2022 | 10:10h | UTC

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis – Cochrane Library

Summary: Which combinations of medicines are best for the prevention and treatment of anaemia in people with cancer? – Cochrane Library

 


5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.

23 Jun, 2022 | 09:55h | UTC

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)

Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.

21 Jun, 2022 | 10:48h | UTC

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.

20 Jun, 2022 | 00:51h | UTC

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

 


10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.

20 Jun, 2022 | 00:49h | UTC

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.

15 Jun, 2022 | 11:17h | UTC

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

 


Recommendations Statement: Diagnosis and treatment of systemic mastocytosis.

14 Jun, 2022 | 11:03h | UTC

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel – Hematology, Transfusion and Cell Therapy

 


Cohort Study: Mortality among patients undergoing blood transfusion in relation to donor sex and parity.

14 Jun, 2022 | 10:56h | UTC

Mortality Among Patients Undergoing Blood Transfusion in Relation to Donor Sex and Parity: A Natural Experiment – JAMA Internal Medicine

News Release: Red blood cell units from female blood donors do not increase risk of death of transfused patients – Karolinska Institutet

 


Molecular international prognostic scoring system for myelodysplastic syndromes.

14 Jun, 2022 | 10:38h | UTC

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence

 


BSH guideline for the hematological management of major hemorrhage.

13 Jun, 2022 | 10:53h | UTC

A guideline for the haematological management of major haemorrhage: a British Society for Haematology Guideline – British Journal of Haematology

 


2-year follow-up of a single-arm study: Ciltacabtagene Autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma.

13 Jun, 2022 | 07:34h | UTC

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up – Journal of Clinical Oncology

Original Study: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review: Evidence-based perioperative diagnosis and management of pulmonary embolism.

9 Jun, 2022 | 10:34h | UTC

Evidence-based perioperative diagnosis and management of pulmonary embolism: A systematic review – Annals of Medicine and Surgery

 


Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

9 Jun, 2022 | 10:17h | UTC

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort – Blood

 


International consensus classification of mature lymphoid neoplasms.

9 Jun, 2022 | 10:15h | UTC

The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee – Blood

 


Cardiac Magnetic Resonance Imaging–based screening for cardiac sarcoidosis in patients with atrioventricular block requiring temporary pacing.

8 Jun, 2022 | 10:41h | UTC

Cardiac Magnetic Resonance Imaging–Based Screening for Cardiac Sarcoidosis in Patients With Atrioventricular Block Requiring Temporary Pacing – Journal of the American Heart Association

Invited Commentary: Managing Patients With Advanced Atrioventricular Block: The Essential Role of Cardiovascular Magnetic Resonance Imaging for Timely and Accurate Diagnosis – Journal of the American Heart Association

 


ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.

7 Jun, 2022 | 10:52h | UTC

ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children – Radiotherapy & Oncology

 


Oncologic emergencies and urgencies: A comprehensive review.

6 Jun, 2022 | 12:06h | UTC

Oncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians

 

Commentary on Twitter

 


#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.

6 Jun, 2022 | 11:16h | UTC

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center

Commentary: Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma – The ASCO Post

 


#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.

6 Jun, 2022 | 11:11h | UTC

Teclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine

 

Commentary on Twitter

 


#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.

6 Jun, 2022 | 11:06h | UTC

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute

 

Commentary on Twitter

 


Brief Review: Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery.

6 Jun, 2022 | 10:55h | UTC

Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery – American Journal of Medicine

 


BSH Guidelines for thrombophilia testing.

2 Jun, 2022 | 11:28h | UTC

Guidelines for thrombophilia testing: A British Society for Haematology guideline

 


NIH Updated Guideline: Antithrombotic therapy in patients with COVID-19.

2 Jun, 2022 | 11:25h | UTC

Antithrombotic Therapy in Patients With COVID-19 – National Institutes of Health

 


Cohort Study: Risk of hematologic cancer in patients with undifferentiated pruritus.

30 May, 2022 | 10:35h | UTC

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live

 


Stay Updated in Your Specialty

No spam, just news.